Morgan Stanley Upgrades Insmed to Overweight, Raises Price Target to $212

Benzinga Newsdesk www.benzinga.com Positive 90.6%

Neg 0% Neu 0% Pos 90.6%

Morgan Stanley analyst Matthew Harrison upgrades Insmed (NASDAQ:INSM) from Equal-Weight to Overweight and raises the price target from $166 to $212.